publication . Article . 2020

On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2

Allan Sauvat; Fabiola Ciccosanti; Francesca Colavita; Martina Di Rienzo; Concetta Castilletti; Maria Rosaria Capobianchi; Oliver Kepp; Laurence Zitvogel; Gian Maria Fimia; Mauro Piacentini; ...
Open Access English
  • Published: 19 Aug 2020
  • Publisher: HAL CCSD
  • Country: France
Abstract
<jats:title>Abstract</jats:title><jats:p>The current epidemic of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) calls for the development of inhibitors of viral replication. Here, we performed a bioinformatic analysis of published and purported SARS-CoV-2 antivirals including imatinib mesylate that we found to suppress SARS-CoV-2 replication on Vero E6 cells and that, according to the published literature on other coronaviruses is likely to act on-target, as a tyrosine kinase inhibitor. We identified a cluster of SARS-CoV-2 antivirals with characteristics of lysosomotropic agents, meaning that they are li...
Persistent Identifiers
Subjects
Medical Subject Headings: viruses
free text keywords: [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM], [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Cancer Research, Cell Biology, Cellular and Molecular Neuroscience, Immunology, Article, Virtual screening, Viral infection, Vero cell, Imatinib mesylate, Ponatinib, chemistry.chemical_compound, chemistry, Medicine, business.industry, business, Viral replication, Tyrosine-kinase inhibitor, medicine.drug_class, Siramesine, medicine.drug, Chloroquine, Coronavirus, medicine.disease_cause, Pharmacology, lcsh:Cytology, lcsh:QH573-671
Related Organizations
Funded by
EC| EVAg
Project
EVAg
European Virus Archive goes global
  • Funder: European Commission (EC)
  • Project Code: 653316
  • Funding stream: H2020 | RIA
Validated by funder
,
ANR| Université de Paris
Project
Université de Paris
Université de Paris
  • Funder: French National Research Agency (ANR) (ANR)
  • Project Code: ANR-18-IDEX-0001
Communities
COVID-19
51 references, page 1 of 4

1. Raoult, D., Zumla, A., Locatelli, F., Ippolito, G. & Kroemer, G. Coronavirus infections: epidemiological, clinical and immunological features and hypotheses. Cell Stress 4, 66-75 (2020). [OpenAIRE]

2. Bojkova, D. et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature https://doi.org/10.1038/s41586-020-2332-7 (2020).

3. Guha, R. Chemical informatics functionality in R. 2007 18, 16 (2007).

4. Cao, Y., Charisi, A., Cheng, L. C., Jiang, T. & Girke, T. ChemmineR: a compound mining framework for R. Bioinformatics 24, 1733-1734 (2008). [OpenAIRE]

5. Yao, X. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. https://doi.org/10.1093/ cid/ciaa237 (2020).

6. Tang, W. et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 369, m1849 (2020).

7. Mahevas, M. et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 369, m1844 (2020).

8. Boulware, D. R. et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. New Engl. J. Med. https://doi.org/10.1056/ NEJMoa2016638 (2020).

9. Liu, W. et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis. Can. Med. Assoc. J. https://doi.org/10.1503/ cmaj.200647 (2020).

10. Boya, P. et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22, 3927-3936 (2003).

11. Boya, P. & Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene 27, 6434-6451 (2008).

12. Briggs, I. & Barnes, J. C. Actions of opioids on the dorsal root potential of the isolated spinal cord preparation of the neonate rat. Neuropharmacology 26, 469-475 (1987).

13. Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368, 409-412 (2020).

14. Yuan, S. et al. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacol. Res. https://doi.org/ 10.1016/j.phrs.2020.104960 (2020).

15. Adeoye, A. O., Oso, B. J., Olaoye, I. F., Tijjani, H. & Adebayo, A. I. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus. J. Biomol. Struct. Dyn. https://doi.org/10.1080/07391102.2020.1765876 (2020).

51 references, page 1 of 4
Any information missing or wrong?Report an Issue